ArticleOncotarget2016
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Koichi Takahashi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
55 papers cite it
this paperpooled ittrialcites it